HCM (HUTCHMED (China) Limited) Stock Market Reviews

crown

search

Read and share opinions on HCM (HUTCHMED (China) Limited) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

HCM

HUTCHMED (China) Limited

clarify Drug Manufacturers - Specialty & Generic

bookmark Healthcare

public Hong Kong

Sell Neutral Buy

Latest News

HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®
Nov 5, 2025
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
Oct 14, 2025
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
Oct 13, 2025
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025
Oct 2, 2025
Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025
Sep 12, 2025
HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025
Sep 5, 2025
HUTCHMED Announces Appointment of Acting Chief Executive Officer
Aug 25, 2025
HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
Aug 20, 2025
Best Momentum Stock to Buy for August 19th
Aug 19, 2025
HUTCHMED (China) First Half 2025 Earnings: EPS: US$0.53 (vs US$0.03 in 1H 2024)
Aug 9, 2025
HUTCHMED Reports 2025 Interim Results
Aug 7, 2025
HUTCHMED to Announce 2025 Half-Year Financial Results
Jul 3, 2025
HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy
Jun 30, 2025
How Much Upside is Left in HUTCHMED (HCM)? Wall Street Analysts Think 73.52%
Jun 23, 2025

Reviews